SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sarandol, A.
Right arrow Articles by Sarandol, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarandol, A.
Right arrow Articles by Sarandol, E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment

Asli Sarandol

Department of Psychiatry, Uludag University Medical Faculty, Bursa, Turkey, asli{at}uludag.edu.tr

Selcuk Kirli

Department of Psychiatry, Uludag University Medical Faculty, Bursa, Turkey

Cengiz Akkaya

Department of Psychiatry, Uludag University Medical Faculty, Bursa, Turkey

Nihal Ocak

Department of Psychiatry, Uludag University Medical Faculty, Bursa, Turkey

Esma Eroz

Department of Psychiatry, Uludag University Medical Faculty, Bursa, Turkey

Emre Sarandol

Department of Psychiatry, Uludag University Medical Faculty, Bursa, Turkey

The aim of the present study was to investigate serum paraoxonase/arylesterase activities and oxidation/oxidizability of apolipoprotein B-containing lipoproteins and several coronary artery disease risk factors, including homocysteine, high sensitive C-reactive protein, tumour necrosis factor-{alpha}, leptin and adiponectin in patients with schizophrenia. Oxidation of lipoproteins plays an important role in atherogenesis, and the enzyme paraoxonase has been shown to prevent lipoprotein oxidation. Furthermore, low paraoxonase activity has been suggested to predict coronary artery disease. Forty patients who fully met the fourth Diagnostic and Statistical Manual of Mental Disorders criteria for schizophrenia and 35 healthy control subjects were included in the study. Serum paraoxonase/arylesterase activities were determined spectrophotometrically. Malondialdehyde levels of apolipoprotein B-containing lipoproteins were determined before and after incubation with copper-sulphate, which yielded basal- and {Delta}-malondialdehyde values, respectively. Homocysteine and highly sensitive C-reactive protein levels were determined using a fluorescence-polarization immunoassay and immunonephelometry, respectively. Leptin and adiponectin levels were measured with radioimmunoassay and tumour necrosis factor-{alpha} was determined by enzyme linked immunosorbent assay. Serum paraoxonase and arylesterase activities were significantly lower and {Delta}-malondialdehyde levels were significantly higher in the schizophrenia group compared with the control group. However, there were not any significant differences in other parameters of the study between the study groups. There was a significant increase in body mass index and serum triglyceride and very low density lipoprotein cholesterol levels in the schizophrenic group after 6 weeks of treatment. These parameters were significantly increased in patients treated with atypical antipsychotics but not in patients treated with typic or long acting antipsychotics. The results of the present study suggest that patients with schizophrenia might have increased risk for coronary artery disease related to reduced serum paraoxonase activity and increased oxidizability of apolipoprotein B-containing lipoproteins.

Key Words: adiponectin • antipsychotic • high sensitive C-reactive protein • homocysteine • leptin • lipoprotein oxidation • paraoxonase • schizophrenia • tumour necrosis factor-{alpha}

References

  • American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatric Association, Washington, DC.
  • Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez JM, Navarro MA, San L. ( 2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65: 1335—1342[Web of Science][Medline] [Order article via Infotrieve]
  • Atmaca M., Kuloglu M., Tezcan E., Ustundag B. (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64: 598—604[Web of Science][Medline] [Order article via Infotrieve]
  • Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. (1998) Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 101: 1581—1590[Web of Science][Medline] [Order article via Infotrieve]
  • Baptista T., Beaulieu S. (2002) Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry 47: 742—749[Web of Science][Medline] [Order article via Infotrieve]
  • Belo L., Caslake M., Gaffney D., Santos-Silva A., Pereira-Leite L., Quintanilha A., Rebelo I. (2002) Changes in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis 162: 425—432[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Beltowski J. (2005) Protein homocysteinylation: a new mechanism of atherogenesis? Postepy Hig Med Dosw 59: 392—404
  • Beltowski J. (2006) Leptin and atherosclerosis. Atherosclerosis 189: 47—60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Buege J.A., Aust S.D. (1978) Microsomal lipid peroxidation. Methods Enzymol 52: 302—310[Medline] [Order article via Infotrieve]
  • Cao H., Girard-Globa A., Berthezene F., Moulin P. (1999) Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-R polymorphism. J Lipid Res 40: 133—139[Abstract/Free Full Text]
  • Cohn T.A., Remington G., Zipursky R.B., Azad A., Connolly P., Wolever T M S (2006) Insulin resistance and adiponectin levels in drug, free patients with schizophrenia: A preliminary report. Can J Psychiatry 51: 382—386[Web of Science][Medline] [Order article via Infotrieve]
  • Clarke R. and Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015—2022[Abstract/Free Full Text]
  • Curkendall S.M., Jingping M., Glasser D.B., Rose-Stang M., Jones J.K. (2004) Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. Br J Psychiatry 65: 715—720[CrossRef]
  • Eckerson H.W., Wyte M.C., La Du B.N. (1983) The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35: 1126—1138 Feingold K.R., Menon R.A., Moser A.H., Grunfeld C. (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139: 307—315[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Friedewald W.T., Levy R.I., Fredrickson D.S. (1972) Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499—508[Abstract]
  • Gan K.N., Smolen A., Eckerson H.W., La Du B.N. (1991) Purification of human serum paraoxonase/arylesterase: Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19: 100—106[Abstract]
  • Haagen L., Brock A. (1992) A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 30: 391—395
  • Hennekens C.H., Hennekens A.R., Hollar D., Casey D.E. (2005) Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150: 1115—1121[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Herran A., Garcia-Unzueta M.T., Amado J.A., de La Maza M.T., Alvarez C., Vazquez-Barquero J.L. (2001) Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 179: 59—62[Abstract/Free Full Text]
  • Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., Kanai A., Kase A., Uchikado H., Hirayasu Y. (2006) Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20: 75—79[Abstract/Free Full Text]
  • Huang T.L., Chen J.F. (2005) Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res 80: 55—59[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jakubowski H. (2000) Calcium-dependent human serum homocysteine thiolactone hydrolyse: a protective mechanism against protein N-homocysteinylation. J Biol Chem 275: 3957—3962[Abstract/Free Full Text]
  • Jarvik G.P., Rozek L.S., Brophy V.H., Hatsukami T.S., Richter R.J., Schellenberg G.D., Furlog C.E. (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 Genotype. Arterioscler Thromb Vasc Biol 20: 2441—2447[Abstract/Free Full Text]
  • Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. (1998) Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97: 1029—1036[Abstract/Free Full Text]
  • Jow G.M., Yang T.T., Chen C.L. (2006) Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord 90: 21—27[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kerkeni M., Addad F., Chauffert M., Chuniaud L., Miled A., Trivin F., Maaroufi K. (2006) Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem 39: 821—825[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kivircik B.B., Alptekin K., Caliskan S., Comlekci A., Oruk G., Tumuklu M., Kurklu K., Arkar H., Turk A., Caliskan M., Yesil S. (2003) Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 795—799[CrossRef][Medline] [Order article via Infotrieve]
  • Levine J., Sela B.A., Osher Y., Belmaker R.H. (2005) High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 29: 1181—1191[CrossRef][Medline] [Order article via Infotrieve]
  • Levine J., Stahl Z., Sela B.A., Gavendo S., Ruderman V., Belmaker R.H. (2002) Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 159: 1790—1792[Abstract/Free Full Text]
  • Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., Mackness M. (2003) Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107: 2775—2779[Abstract/Free Full Text]
  • Mackness B., Davies G K., Turkie W., Lee E., Roberts D H., Hill E., Roberts C., Durrington P N., Mackness M I. (2001) Paraoxonase status in coronary hesrt disease: Are activity and concentration more important than genotype? Arterioscler Thromb vasc Biol 21: 1451—1457[Abstract/Free Full Text]
  • Mackness M.I., Arrol S., Abbott C.A., Durrington P.N. (1993) Protection of low-density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 104: 129—135[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mackness M.I., Harty D., Bhatnagar D., Winocour P.H., Arrol S., Ishola M., Durrington P.N. (1991) Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 86: 193—199[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Matsumoto C., Ohmori O., Hori H., Shinkai T., Nakamura J. (2002) Analysis of association between the Gln192Arg polymorphism of the paraoxonase gene and schizophrenia in humans. Neurosci Lett 321: 165—168[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Matsuzawa Y. (2006) Therapy insight: Adipocytokines in metabolic syndrome and related cardiovascular disease. Cardiovascular Medicine nat Clin Pract Cardiovasc Med 3: 35—42
  • McCreadie R.G. (2003) Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 183: 534—539[Abstract/Free Full Text]
  • Melkersson K., Dahl M.L. (2004) Adverse metabolic effects associated with atypical antipsychotics: Literature revew and clinical implications. Drugs 64: 701—723[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mosca L., Rubenfire M., Tarshis T., Tsai A., Pearson T. (1997) Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. Am J Cardiol 80: 825—830[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Monteleone P., Fabrazzo M., Tortorella A., Maj M. ( 1997) Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 71: 11—17[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Muntjewerff J.W., Kahn R.S., Blom H.J., den Heijer M (2006) Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 11: 143—149[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Naudin J., Capo C., Giusano B., Mege J.L., Azorin JM (1997) A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res 26: 227—233[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Newcomer J.W., Haupt D.W. (2006) The metabolic effects of antipsychotic medications. Can J Psychiatry 51: 480—491[Web of Science][Medline] [Order article via Infotrieve]
  • PischonGirman C.J., Hotamisligil G.S., Rifai N., Hu F B., Rimm E.B. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730—1737[Abstract/Free Full Text]
  • Pischon T., Rimm E.B. (2006) Adiponectin: a promising marker for cardiovascular disease. Clin Chem 52: 797—799[Free Full Text]
  • Rashid S., Watanabe T., Sakaue T., Lewis G.F. (2003 ) Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity Clin Biochem 36: 421—429[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Reif A., Pfuhlmann B., Lesch K.P. (2005) Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. Prog Neuropsychopharmacol Biol Psychiatry 29: 1162—1168[CrossRef][Medline] [Order article via Infotrieve]
  • Rifai N., Ridker P.M. (2001) High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease. Clin Chem 47: 403—411[Abstract/Free Full Text]
  • Ross R. ( 1999) Atherosclerosis is an inflammatory disease. N Engl J Med 340: 115—126[Free Full Text]
  • Sporn A.L., Bobb A.J., Gogtay N., Stevens H., Greenstein D.K., Clasen L.S., Tossell J.W., Nugent T., Gochman P.A., Sharp W.S., Mattai A., Lenane M.C., Yanovski J.A., Rapoport J.L. (2005) Hormonal correlates of clozapine-induced weight gain in psychotic children. An exploratory study. J Am Acad Child Adolesc Psychiatry 44: 925—933[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Susser E., Brown A.S., Klonowski E., Allen R.H., Lindenbaum J. (1998) Schizophrenia and impaired homocysteine metabolism: a possible association. Biol Psychiatry 44: 141—143[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sytherland W H.F., Walker R.J., de Jong S.A., van Rij A.M., Phillips V., Walker H.L. (1999) Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol 19: 1340—1347[Abstract/Free Full Text]
  • Varga Z., Paragh G., Seres I., Kakuk G., Karanyi Z., Karpati I., Matyus J., Csongradi E., Juhasz A., Balla J., Bajnok L. (2006) Hyperleptinemia is not responsible for decreased paraoxonase activity in hemodialysis patients. Nephron Clin Pract 103: 114—120[CrossRef]
  • Tribble D.L., Holl L.G., Wood P.D., Krauss R.M. (1992) Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93: 189—199[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Virgos C., Martorell L., Simo J.M. et al. (1999) Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. NeuroReport 10: 2035—2038[Web of Science][Medline] [Order article via Infotrieve]
  • Witzum J.L. (1994) The oxidation hypothesis of atherosclerosis. Lancet 344: 793—795[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zhang A., Vertommen J., Van Gaal L, De Leeuw I. (1993) A rapid and simple method for measuring the susceptibility of low-density lipoprotein and very-low-density lipoprotein to copper-catalyzed oxidation. Clin Chim Acta 227: 159—173[CrossRef][Web of Science]

This version was published on November 1, 2007

Journal of Psychopharmacology, Vol. 21, No. 8, 857-863 (2007)
DOI: 10.1177/0269881107077609
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sarandol, A.
Right arrow Articles by Sarandol, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarandol, A.
Right arrow Articles by Sarandol, E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement